Mimedx Group, Inc · NASDAQ:MDXG
Mimedx — Bank of America Securities 2021 Virtual Healthcare Conference
7 slides from Mimedx's conference presentation, May 12, 2021
Slide 1: Advancing regenerative medicine treatment through placental science
Advancing regenerative Medicine treatment through placental science Bank of America Securities 2021 Virtual Healthcare Conference May 13, 2021 Exhibit 99.1
Slide 2: Disclaimer & Cautionary Statements
Disclaimer & Cautionary Statements Important Cautionary Statement This presentation includes forward-looking statements. Forward-looking statements are subject to risks and uncertainties, and the Company cautions investors against placing undue reliance on such statements. Actual results may differ
Slide 3: Industry leader in utilizing amniotic tissue as a platform for regenerative medicine
INDUSTRY LEADER IN UTILIZING AMNIOTIC TISSUE AS A PLATFORM FOR REGENERATIVE MEDICINE Distinct drivers of significant shareholder value with current and future growth potential Base Business Advanced Wound Care Promising Late-Stage Pipeline Musculoskeletal
Slide 4: Clear strategy for value creation
CLEAR STRATEGY FOR VALUE CREATION 2021 2022 2023 2024 Industry leading base business with high gross margins provides foundation for long-term, stable growth, fueling late-stage pipeline Targeting 10%+ growth in base advanced wound care business Japan approval anticipated mid-2021; providing foundat
Slide 5: Industry – FDA interactions during development
Initial IND Submissions End of Phase 2 Meeting Pre-BLA or NDA Meeting Market Application Submissions Basic Research Prototype Design or Discovery Preclinical Development Clinical Development FDA Filing / Approval & Launch Preparation Phase 1 Phase 3 Phase 2 IND Review Phase and Ongoing Submissions A
Slide 6: Investing heavily in promising late-stage pipeline with significant growth opportunities
Current IND Studies Planned Near-Term IND Studies INVESTING HEAVILY IN PROMISING LATE-STAGE PIPELINE WITH SIGNIFICANT GROWTH OPPORTUNITIES Announced last patients last visits in three late-stage trials Top-line data readouts anticipated late-summer 2021 Intend to initiate Phase 3 study Knee Osteoart
Slide 7: From foundation to transformation
FROM FOUNDATION TO TRANSFORMATION Positioning for pipeline acceleration Focusing capital on strategic initiatives Investing in base business for growth
MiMedx Group — Bank of America Securities 2021 Virtual Healthcare Conference on 6ix